Possible therapeutic vaccine strategy against human immunodeficiency virus escape from reverse transcriptase inhibitors studied in HLA-A2 transgenic mice

Journal of Virology

Volumn 80, Issue 21, 2006, Pages 10645-10651

  Okazaki, Takahiro ^a,b   Terabe, Masaki ^a   Catanzaro, Andrew T ^a,c   Pendleton, C David ^a   Yarchoan, Robert ^a   Berzofsky, Jay A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GLYCYLISOLEUCYLLEUCYLGLYCYLPHENYLALANYLVALYLPHENYLALANYLTHREONYLLEUCINE; HLA A2 ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; ISOLEUCYLVALYLISOLEUCYLTYROSYLGLUTAMINYLTYROSYLMETHIONYLASPARTYLASPARTYLLEUCINE; ISOLEUCYLVALYLISOLEUCYLTYROSYLGLUTAMINYLTYROSYLVALYLASPARTYLASPARTYLLEUCINE; PEPTIDE VACCINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TYROSYLLEUCYLTYROSYLGLUTAMINYLISOLEUCYLASPARTYLASPARTYLVALINE; TYROSYLLEUCYLTYROSYLGLUTAMINYLTYROSYLVALYLASPARTYLASPARTYLVALINE; UNCLASSIFIED DRUG; VALYLISOLEUCYLTYROSYLGLUTAMINYLTYROSYLMETHIONYLASPARTYLASPARTYLLEUCINE; VALYLISOLEUCYLTYROSYLGLUTAMINYLTYROSYLMETHIONYLASPARTYLASPARTYLVALINE; VALYLISOLEUCYLTYROSYLGLUTAMINYLTYROSYLVALYLASPARTYLASPARTYLLEUCINE; VALYLLEUCYLTYROSYLGLUTAMINYLTYROSYLVALYLASPARTYLASPARTYLVALINE;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ANTIGENICITY; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CROSS REACTION; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE; VIRUS MUTATION; VIRUS RESISTANCE;

AIDS VACCINES; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMALS; DRUG RESISTANCE, VIRAL; EPITOPES; HIV; HIV-1 REVERSE TRANSCRIPTASE; HLA-A2 ANTIGEN; HUMANS; MICE; MICE, TRANSGENIC; MODELS, IMMUNOLOGICAL; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS; T-LYMPHOCYTES, CYTOTOXIC;

HUMAN IMMUNODEFICIENCY VIRUS; MUS MUSCULUS;

EID: 33750317428     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.01351-05     Document Type: Article

References (22)

1. Berzofsky, J. A., J. Ahlers, J. Janik, J. Morris, S. Oh, M. Terabe, and I. M. Belyakov. 2004. Progress on new vaccine strategies against chronic viral infections. J. Clin. Investig. 114:450-462.
2. Berzofsky, J. A., J. D. Ahlers, and I. M. Belyakov. 2001. Strategies for designing and optimizing new generation vaccines. Nat. Rev. Immunol. 1:209-219.
3. Boucher, C. A., N. Cammack, P. Schipper, R. Schuurman, P. Rouse, M. A. Wainberg, and J. M. Cameron. 1993. High-level resistance to (-) enantiomeric 2′-deoxy-3′-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 37:2231-2234.
4. Carpenter, C. C., M. A. Fischl, S. M. Hammer, M. S. Hirsch, D. M. Jacobsen, D. A. Katzenstein, J. S. Montaner, D. D. Richman, M. S. Saag, R. T. Schooley, M. A. Thompson, S. Vella, P. G. Yeni, and P. A. Volberding. 1998. Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA panel. JAMA 280:78-86.
5. Firat, H., S. Tourdot, A. Ureta-Vidal, A. Scardino, A. Suhrbier, F. Buseyne, Y. Riviere, O. Danos, M. L. Michel, K. Kosmatopoulos, and F. A. Lemonnier. 2001. Design of a polyepitope construct for the induction of HLA-A0201-restricted HIV 1-specific CTL responses using HLA-A*0201 transgenic, H-2 class I KO mice. Eur. J. Immunol. 31:3064-3074.
6. Gao, Q., Z. Gu, M. A. Parniak, J. Cameron, N. Cammack, C. Boucher, and M. A. Wainberg. 1993. The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2′,3′-dideoxyinosine and 2′,3′-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2′,3′-dideoxy-3′-thiacytidine. Antimicrob. Agents Chemother. 37:1390-1392.
7. Gotch, F. M., J. Rothbard, K. Howland, A. R. M. Townsend, and A. J. McMichael. 1987. Cytotoxic T lymphocytes recognize a fragment of influenza virus matrix protein in association with HLA-A2. Nature 326:881-882.
8. Harrer, E., T. Harrer, P. Barbosa, M. Feinberg, R. P. Johnson, S. Buchbinder, and B. D. Walker. 1996. Recognition of the highly conserved YMDD region in the human immunodeficiency virus type 1 reverse transcriptase by HLA-A2-restricted cytotoxic T lymphocytes from an asymptomatic long-term nonprogressor. J. Infect. Dis. 173:476-479.
9. Johnson, V. A., F. Brun-Vezinet, B. Clotet, B. Conway, R. T. D'Aquila, L. M. Demeter, D. R. Kuritzkes, D. Pillay, J. M. Schapiro, A. Telenti, and D. D. Richman. 2003. Drug resistance mutations in HIV-1. Top. HIV Med. 11:215-221.
10. Newberg, M. H., D. H. Smith, S. B. Haertel, D. R. Vining, E. Lacy, and V. H. Engelhard. 1996. Importance of MHC class 1 α2 and α3 domains in the recognition of self and non-self MHC molecules. J. Immunol. 156:2473-2480.
11. Nijman, H. W., J. G. A. Houbiers, M. P. M. Vierboom, S. H. van der Burg, J. W. Drijfhout, J. D'Amaro, P. Kenemans, C. J. M. Melief, and W. M. Kast. 1993. Identification of peptide sequences that potentially trigger HLA-A2.1-restricted cytotoxic T lymphocytes. Eur. J. Immunol. 23:1215-1219.
12. Okazaki, T., D. C. Pendleton, F. Lemonnier, and J. A. Berzofsky. 2003. Epitope-enhanced conserved HIV-1 peptide protects HLA-A2-transgenic mice against virus expressing HIV-1 antigen. J. Immunol. 171:2548-2555.
13. + T lymphocytes from β2 microglobulin (β2m) HLA-A2.1 monochain transgenic H-2Db β2m double knockout mice. J. Exp. Med. 185:2043-2051.
14. Pluda, J. M., S. Broder, and R. Yarchoan. 1992. Therapy of AIDS and AIDS-associated neoplasms. Cancer Chemother. Biol. Response Modif. 13:404-439.
15. Rammensee, H. G., T. Friede, and S. Stevanoviic. 1995. MHC ligands and peptide motifs: first listing. Immunogenetics 41:178-228.
16. Reijers, M. H., G. J. Weverling, S. Jurriaans, F. W. Wit, H. M. Weigel, R. W. Ten Kate, J. W. Mulder, P. H. Frissen, R. van Leeuwen, P. Reiss, H. Schuitemaker, F. de Wolf, and J. M. Lange. 1998. Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam Duration of Antiretroviral Medication (ADAM) study. Lancet 352:185-190.
17. Sarafianos, S. G., K. Das, A. D. Clark, Jr., J. Ding, P. L. Boyer, S. H. Hughes, and E. Arnold. 1999. Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with beta-branched amino acids. Proc. Natl. Acad. Sci. USA 96:10027-10032.
18. Sarobe, P., C. D. Pendleton, T. Akatsuka, D. Lau, V. H. Engelhard, S. M. Feinstone, and J. A. Berzofsky. 1998. Enhanced in vitro potency and in vivo immunogenicity of a CTL epitope from hepatitis C virus core protein following amino acid replacement at secondary HLA-A2.1 binding positions. J. Clin. Investig. 102:1239-1248.
19. Schmitt, M., E. Harrer, A. Goldwich, M. Bauerle, I. Graedner, J. R. Kalden, and T. Harrer. 2000. Specific recognition of lamivudine-resistant HIV-1 by cytotoxic T lymphocytes. AIDS 14:653-658.
20. Schuurman, R., M. Nijhuis, R. van Leeuwen, P. Schipper, D. de Jong, P. Collis, S. A. Danner, J. Mulder, C. Loveday, C. Christopherson, S. Kwok, J. Sninsky, and C. A. B. Boucher. 1995. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J. Infect. Dis. 171:1441-1449.
21. Tourdot, S., A. Scardino, E. Saloustrou, D. A. Gross, S. Pascolo, P. Cordopatis, F. A. Lemonnier, and K. Kosmatopoulos. 2000. A general strategy to enhance immunogenicity of low-affinity HLA-A2. 1-associated peptides: implication in the identification of cryptic tumor epitopes. Eur. J. Immunol. 30:3411-3421.
22. Wainberg, M. A., H. Salomon, Z. Gu, J. S. G. Montaner, T. P. Cooley, R. McCaffrey, J. Ruedy, M. H. Hilary, N. Cammack, J. Cameron, and W. Nicholson. 1995. Development of HIV-1 resistance to (-)2′-deoxy-3′-thiacytidine in patients with AIDS or advanced AIDS-related complex. AIDS 9:351-357.